Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives

BackgroundLipid-soluble thiamine precursors have a much higher bioavailability than genuine thiamine and therefore are more suitable for therapeutic purposes. Benfotiamine (S-benzoylthiamine O-monophosphate), an amphiphilic S-acyl thiamine derivative, prevents the progression of diabetic complications, probably by increasing tissue levels of thiamine diphosphate and so enhancing transketolase activity. As the brain is particularly sensitive to thiamine deficiency, we wanted to test whether intracellular thiamine and thiamine phosphate levels are increased in the brain after oral benfotiamine administration.ResultsBenfotiamine that is practically insoluble in water, organic solvents or oil was solubilized in 200 mM hydroxypropyl-β-cyclodextrin and the mice received a single oral administration of 100 mg/kg. Though thiamine levels rapidly increased in blood and liver to reach a maximum after one or two hours, no significant increase was observed in the brain. When mice received a daily oral administration of benfotiamine for 14 days, thiamine derivatives were increased significantly in the liver but not in the brain, compared to control mice. In addition, incubation of cultured neuroblastoma cells with 10 μM benfotiamine did not lead to increased intracellular thiamine levels. Moreover, in thiamine-depleted neuroblastoma cells, intracellular thiamine contents increased more rapidly after addition of thiamine to the culture medium than after addition of benfotiamine for which a lag period was observed.ConclusionOur results show that, though benfotiamine strongly increases thiamine levels in blood and liver, it has no significant effect in the brain. This would explain why beneficial effects of benfotiamine have only been observed in peripheral tissues, while sulbutiamine, a lipid-soluble thiamine disulfide derivative, that increases thiamine derivatives in the brain as well as in cultured cells, acts as a central nervous system drug. We propose that benfotiamine only penetrates the cells after dephosphorylation by intestinal alkaline phosphatases. It then enters the bloodstream as S-benzoylthiamine that is converted to thiamine in erythrocytes and in the liver. Benfotiamine, an S-acyl derivative practically insoluble in organic solvents, should therefore be differentiated from truly lipid-soluble thiamine disulfide derivatives (allithiamine and the synthetic sulbutiamine and fursultiamine) with a different mechanism of absorption and different pharmacological properties.

[1]  M. Todaro,et al.  Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis , 2006, Diabetologia.

[2]  L. Lykouras,et al.  Sulbutiamine, an ‘innocent’ over the counter drug, interferes with therapeutic outcome of bipolar disorder , 2006, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[3]  M. Fujiwara,et al.  “ALLITHIAMINE” A NEWLY FOUND DERIVATIVE OF VITAMIN B1II. THE EFFECT OF ALLITHIAMINE ON LIVING ORGANISM , 1954 .

[4]  Thiamine and its derivatives inhibit delayed rectifier potassium channels of rat cultured cortical neurons , 1998, Neuropharmacology.

[5]  J. Greenwood,et al.  Kinetics of thiamine transport across the blood‐brain barrier in the rat. , 1982, The Journal of physiology.

[6]  K. Okamoto,et al.  A New Thiamine Derivative, S-Benzoylthiamine O-Monophosphate , 1961, Science.

[7]  D. Lonsdale Thiamine tetrahydrofurfuryl disulfide: a little known therapeutic agent. , 2004, Medical Science Monitor.

[8]  M. Besson,et al.  Evidence for a modulatory effect of sulbutiamine on glutamatergic and dopaminergic cortical transmissions in the rat brain , 2000, Neuroscience Letters.

[9]  M. Kanno,et al.  Inhibition of the delayed rectifier K current in guinea-pig cardiomyocytes by thiamine tetrahydrofurfuryl disulfide , 1998, Naunyn-Schmiedeberg's Archives of Pharmacology.

[10]  H. Woelk,et al.  Benfotiamine in treatment of alcoholic polyneuropathy: an 8-week randomized controlled study (BAP I Study). , 1998, Alcohol and alcoholism.

[11]  C. Sheline,et al.  Free radical-mediated neurotoxicity may be caused by inhibition of mitochondrial dehydrogenases in vitro and in vivo , 2006, Neuroscience.

[12]  D. Lonsdale A Review of the Biochemistry, Metabolism and Clinical Benefits of Thiamin(e) and Its Derivatives , 2006, Evidence-based complementary and alternative medicine : eCAM.

[13]  L. Bettendorff,et al.  Thiamine triphosphate and thiamine triphosphatase activities: from bacteria to mammals , 2003, Cellular and Molecular Life Sciences CMLS.

[14]  H. Baelde,et al.  Induction of glomerular alkaline phosphatase after challenge with lipopolysaccharide , 2003, International journal of experimental pathology.

[15]  G. Mazzucchelli,et al.  Discovery of a natural thiamine adenine nucleotide. , 2007, Nature chemical biology.

[16]  D. Grüneklee,et al.  Bioavailability assessment of the lipophilic benfotiamine as compared to a water-soluble thiamin derivative. , 1991, Annals of nutrition & metabolism.

[17]  H. Hammes,et al.  Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy , 2003, Nature Medicine.

[18]  R. Bitsch,et al.  Comparative bioavailability of various thiamine derivatives after oral administration. , 1998, International journal of clinical pharmacology and therapeutics.

[19]  M. Ziems,et al.  Biokinetic parameters and metabolism of S-benzoylthiamine-O-monophosphate. , 2000, BioFactors.

[20]  Min-Jeong Shin,et al.  Thiamine attenuates hypoxia-induced cell death in cultured neonatal rat cardiomyocytes. , 2004, Molecules and cells.

[21]  L. Bettendorff,et al.  The antitrypanosomal drug melarsoprol competitively inhibits thiamin uptake in mouse neuroblastoma cells , 2006, Cell Biology and Toxicology.

[22]  L. Bettendorff,et al.  Determination of thiamin and its phosphate esters in cultured neurons and astrocytes using an ion-pair reversed-phase high-performance liquid chromatographic method. , 1991, Analytical biochemistry.

[23]  M. Ziems,et al.  Effect of high-dosed thiamine hydrochloride and S-benzoyl-thiamine-O-monophosphate on thiamine-status after chronic ethanol administration. , 2000, BioFactors.

[24]  G. Peterson,et al.  A simplification of the protein assay method of Lowry et al. which is more generally applicable. , 1977, Analytical biochemistry.

[25]  Jun Ren,et al.  Benfotiamine alleviates diabetes-induced cerebral oxidative damage independent of advanced glycation end-product, tissue factor and TNF-α , 2006, Neuroscience Letters.

[26]  C. Destrade,et al.  Chronic administration of sulbutiamine improves long term memory formation in mice: Possible cholinergic mediation , 1985, Pharmacology Biochemistry and Behavior.

[27]  L. Bettendorff,et al.  Injection of sulbutiamine induces an increase in thiamine triphosphate in rat tissues. , 1990, Biochemical pharmacology.

[28]  Helga Stopper,et al.  Benfotiamine exhibits direct antioxidative capacity and prevents induction of DNA damage in vitro , 2008, Diabetes/metabolism research and reviews.

[29]  Paul J Thornalley,et al.  High-dose thiamine therapy counters dyslipidaemia in streptozotocin-induced diabetic rats , 2004, Diabetologia.

[30]  R D Adams,et al.  The Wernicke-Korsakoff syndrome. A clinical and pathological study of 245 patients, 82 with post-mortem examinations. , 1971, Contemporary neurology series.

[31]  Elena Berrone,et al.  Regulation of Intracellular Glucose and Polyol Pathway by Thiamine and Benfotiamine in Vascular Cells Cultured in High Glucose* , 2006, Journal of Biological Chemistry.

[32]  J. Bizot,et al.  Chronic treatment with sulbutiamine improves memory in an object recognition task and reduces some amnesic effects of dizocilpine in a spatial delayed-non-match-to-sample task , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[33]  L. Bettendorff The compartmentation of phosphorylated thiamine derivatives in cultured neuroblastoma cells. , 1994, Biochimica et biophysica acta.

[34]  D. Loew Pharmacokinetics of thiamine derivatives especially of benfotiamine. , 1996, International journal of clinical pharmacology and therapeutics.

[35]  U. Gundert-Remy,et al.  Comparative bioavailability of two vitamin B1 preparations: benfotiamine and thiamine mononitrate. , 1997, European journal of clinical pharmacology.

[36]  Feinberg Jf The Wernicke-Korsakoff syndrome. , 1980 .

[37]  L. Bettendorff,et al.  Mechanism of thiamine transport in neuroblastoma cells. Inhibition of a high affinity carrier by sodium channel activators and dependence of thiamine uptake on membrane potential and intracellular ATP. , 1994, The Journal of biological chemistry.

[38]  M. Porta,et al.  Thiamine and benfotiamine prevent increased apoptosis in endothelial cells and pericytes cultured in high glucose , 2004, Diabetes/metabolism research and reviews.

[39]  A. Ceylan-isik,et al.  High-dose benfotiamine rescues cardiomyocyte contractile dysfunction in streptozotocin-induced diabetes mellitus. , 2006, Journal of applied physiology.

[40]  R. Babaei-Jadidi,et al.  Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. , 2003, Diabetes.

[41]  L. Bettendorff,et al.  Thiamine Deficiency in Cultured Neuroblastoma Cells: Effect on Mitochondrial Function and Peripheral Benzodiazepine Receptors , 1995, Journal of neurochemistry.

[42]  A. Fukamizu,et al.  Benfotiamine Counteracts Glucose Toxicity Effects on Endothelial Progenitor Cell Differentiation via Akt/FoxO Signaling , 2006, Diabetes.